Researchers from University of Salerno Develop Novel Antiviral Therapies Using Escherichia coli Membrane Vesicles

Strategic Insights -

Researchers at the University of Salerno have discovered a novel approach to developing antiviral therapies by functionalizing Escherichia coli (E. coli) membrane vesicles with antiviral peptides. The study, published in the journal Frontiers in Molecular Biosciences, explores the use of E. coli outer membrane vesicles as presentation platforms for the AR-23 antiviral peptide. The research highlights the potential of this approach in developing effective and biocompatible antiviral agents against herpes simplex viruses and SARS-CoV-2.

Key Takeaways:

  • Researchers at the University of Salerno have developed a novel approach to antiviral therapy by functionalizing E. coli membrane vesicles with antiviral peptides.
  • The study used recombinant E. coli cells to produce outer membrane vesicles (OMVs) engineered with the ClyA-AR23 chimeric protein, which demonstrated negligible cytotoxicity effects on VERO-76 cells.
  • The OMVs were used to pre-treat HSV-1, HSV-2, SARS-CoV-2, and PV-1 viruses, with results showing that they effectively impaired HSV-1 and HSV-2 replication cycles in a dose-dependent manner.
  • The researchers concluded that the E. coli OMVs provided a first evidence of antiviral peptide functionalization on membrane vesicles of bacterial origin, with negligible cytotoxicity on VERO-76 cells.
  • The study has significant implications for the development of antiviral therapies, particularly against herpes simplex viruses and SARS-CoV-2.
  • The research was conducted by Francesca Mensitieri and colleagues from the Department of Medicine, Surgery, and Dentistry "Scuola Medica Salernitana" at the University of Salerno.

Statistics:

  • The study involved the production of recombinant E. coli cells to produce OMVs engineered with the ClyA-AR23 chimeric protein.
  • The OMVs were used to pre-treat four different viruses: HSV-1, HSV-2, SARS-CoV-2, and PV-1.
  • The results showed that the OMVs effectively impaired HSV-1 and HSV-2 replication cycles in a dose-dependent manner.
  • The researchers reported negligible cytotoxicity effects on VERO-76 cells.
  • The study demonstrated significant implications for the development of antiviral therapies against herpes simplex viruses and SARS-CoV-2.

Sources:

  • "Outer membrane vesicles from Escherichia coli as a presentation platform for AR-23 antiviral peptide" (Frontiers in Molecular Biosciences, 2025,12).
  • University of Salerno, Department of Medicine, Surgery, and Dentistry "Scuola Medica Salernitana".
  • Francesca Mensitieri, Federica Dell'Annunziata, Giulia Gaudino, Veronica Folliero, Gianluigi Franci, Fabrizio Dal Piaz, Viviana Izzo.